Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent rhIL-2 with HAART in HIV
NCT00000870Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of patients achieving at least 50-percent increase in CD4 counts above prerandomization baseline values at 1 year and Rate of change in CD4 counts. Status: completed.
02
Drugs
aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000870.